Injection Lipolysis — Body Contouring (Phosphatidylcholine)

Injectable fat reduction targeting localised subcutaneous deposits using a phosphatidylcholine-based lipolytic solution combined with L-carnitine, a local anaesthetic and homeopathic compounds. The solution is injected at 10–13 mm depth into the subcutaneous fat layer, where phosphatidylcholine disrupts the fat cell membrane, releasing the fat for elimination by the body's lymphatic and metabolic clearance. At Estetické centrum Praha MUDr. Renata Handlová uses this technique for double chin, abdomen, flanks and other localised deposits that resist diet and exercise.

Injection lipolysis uses the membrane-disrupting properties of phosphatidylcholine (PPC) — a phospholipid naturally present in cell membranes and bile — to selectively destroy adipocytes (fat cells) in the subcutaneous layer when injected in therapeutic concentration. PPC at the doses used for lipolysis emulsifies the fat cell membrane, causing the adipocyte to lyse and release its triglyceride content. The freed fatty acids are then processed by inflammatory macrophages, transported to the liver via the lymphatics and eliminated through normal metabolic pathways over several weeks. At Estetické centrum Praha MUDr. Renata Handlová prepares a lipolytic cocktail containing phosphatidylcholine combined with L-carnitine (which facilitates fatty acid transport into mitochondria for beta-oxidation, enhancing elimination), a local anaesthetic to improve comfort during and after injection, and homeopathic supporting compounds. The solution is injected at 10–13 mm depth — reaching the subcutaneous fat layer — at multiple points across the target area, with each session typically requiring 10–13 ml of solution to adequately cover a localised deposit. Common treatment zones include the submental area (double chin), abdomen, flanks, inner thighs and arms. The inflammatory response following injection lipolysis is pronounced and predictable: the area becomes swollen, warm, tender and may show bruising within hours of treatment, peaking over the first two to three days and substantially resolving within one week. This inflammatory phase is integral to the clearance mechanism — macrophages migrate to the treated area specifically to process the lysed fat cells. Patients should plan for one week of social downtime and should avoid strenuous exercise, heat and alcohol during the acute inflammatory period. Results develop gradually over six to eight weeks as the inflammatory response resolves and the cleared fat cells are removed. The reduction achieved varies by patient and the volume of fat present; some patients see meaningful improvement after a single session while others benefit from two to three sessions spaced at least six to eight weeks apart to avoid accumulation of inflammatory load. Because the destroyed fat cells do not regenerate — adipocytes have limited regenerative capacity in adulthood — the improvement is largely permanent, provided body weight remains stable. Contraindications include pregnancy, type I diabetes, history of stroke or TIA, active bleeding disorders, current anticoagulant or antiplatelet therapy (aspirin, warfarin, heparin) and soy or egg allergy (PPC can be derived from soy lecithin; the anaphylactic risk is low but must be screened). These are assessed at consultation before the first session.